Vaccination with Leishmania Activated C Kinase (LACK) Antigen Induces Immune Response but Failed to Induce Protection against Leishmania donovani Challenge Infection
DOI:
https://doi.org/10.53555/jaz.v42i02.5041Keywords:
Leishmania donovani, vaccine, LACK antigen, cytokineAbstract
Visceral leishmaniasis (VL), caused by Leishmania donovani, is life-threatening, and development of a safe and effective vaccine has been an essential aim for controlling the disease. In this study, Leishmania Activated C Kinase (LACK) Antigen was purified from leishmania antigens. The liposomal formulation of LACK antigen was tested to induce immune response and protection against L. donovani challenge infection. Vaccination with Liposomal LACK induces immune response in BALB/c mice with an elevated level of IFN-g and IL-10. Surprisingly, vaccination was failed to ensure protection in mice. In conclusion, IL-10 probably played the crucial role in vaccine failure.
Downloads
References
1. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
2. Das, A. & N. Ali, 2012. Vaccine Development Against Leishmania donovani. Front. Immunol., 3:99.
3. Ivens, A.C., C.S. Peacock CS, E.A. Worthey EA, et al., 2005 The genome of the kinetoplastid parasite, Leishmania major. Science , 309 (5733): 436–442.
4. Sabu, R.A., S. Bhowmick, R. Chhajer R, S. Ejazi, N. Didwania N, M. Asad, A. Bhattacharyya A, U. Sinha U & N. Ali, 2018. Liposomal elongation factor-1α triggers effector CD4 and CD8 T cells for induction of long-lasting protective immunity against visceral leishmaniasis. Front Immunol, 9:18.
5. Bhowmick, S., R. Ravindran & N. Ali, 2007. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1response. Vaccine , 25 (35):6544–6556.
6. Bhowmick, S. & N. Ali, 2009. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE, 4(6):e5820.
7. Kumari, S., A. Kumar, M. Samant, N. Singh & A. Dube, 2008. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr. Drug. Targets., 9(11):938-47.
8. Salehi-Sangani, G., M. Mohebali, V. Jajarmi, A. Khamesipour, M. Bandehpour, M. Mahmoudi & H. Zahedi-Zavaram, 2019. Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens. Iran. J. Basic. Med. Sci., 22(12):1493-1501.
9. Fernández, L., E. Carrillo, L. Sánchez-Sampedro, C. Sánchez, A.V. Ibarra-Meneses, M.A. Jimenez, V.D.A. Almeida, M. Esteban & J. Moreno, 2018. Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters. Front. Immunol, 9:843.
10. Ghaffarifar, F., O. Jorjani, Z. Sharifi, A. Dalimi, Z.M. Hassan, F. Tabatabaie, F. Khoshzaban & H.Z. Hezarjaribi, 2013. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS, 121(4):290-298.
11. Gurunathan, S., D.L. Sacks, D.R. Brown, S.L. Reiner, H. Charest, N. Glaichenhaus & R.A. Seder, 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med., 186(7):1137-1147.
12. Méndez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M.A. Moga, Y.A. Skeiky, A. Campos-Neto, S. Reed, R.A. Seder & D. Sacks, 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol., 166 (8):5122-128.
13. Coelho, E.A., C.A. Tavares, F.A. Carvalho, K.F. Chaves, K.N. Teixeira, R.C. Rodrigues, H. Charest, G. Matlashewski, R.T. Gazzinelli & A.P. Fernandes, 2003. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect. Immun., 71(7):3988-3994.
14. Dumonteil, E., R.S. Maria Jesus, E.O. Javier & G.M. Maria del Rosario GM. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine, 21(17-18):2161-2168.
15. Gomes, D.C., E.F. Pinto, L.D. de Melo, W.P. Lima, V. Larraga, U.G. Lopes & Rossi-B. Bergmann, 2007. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine, 25(12):2168-2172.
16. Dondji, B., E. Pérez-Jimenez, K. Goldsmith-Pestana, M. Esteban & D. McMahon-Pratt,2005. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect. Immun., 73(8):5286-5289.
17. Marques-da-Silva, E.A., E.A. Coelho, D.C. Gomes, M.C. Vilela, C.Z. Masioli, C.A. Tavares, A.P. Fernandes, L.C. Afonso & S.A. Rezende, 2005. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol. Res. 98:67-74.
18. Melby, P.C., J. Yang, W. Zhao, L.E. Perez & J. Cheng, 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun., 69(8):4719-4725.
19. Murphy, M.L., U. Wille, E.N. Villegas, C.A. Hunter & J.P. Farrell, 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol., 31(10):2848-56.
20. Murray, H.W., C.M. Lu, S. Mauze, S. Freeman, A.L. Moreira, G. Kaplan & R.L. Coffman, 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun., 70(11):6284-6293.
21. Moore, K.W., R. de Waal Malefyt, R.L. Coffman & A. O'Garra, 2001, Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol., 19:683-765.
22. Nylén, S. & D. Sacks, 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trend.s Immunol., 28 (9):378-384.
23. Stober, C.B., U.G. Lange, M.T. Roberts, A. Alcami & J.M. Blackwell, 2005. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J. Immunol.,175:2517-2524.
24. Mills, K.H, 2004. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol., 4(11):841-855.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Sudipta Bhowmick
This work is licensed under a Creative Commons Attribution 4.0 International License.
